Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreement (Details)

v3.22.2
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Aug. 17, 2021
Dec. 17, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenues     $ 28,191 $ 6,620 $ 49,816 $ 7,534
Research and development     11,525 $ 10,091 24,145 $ 19,924
License Agreement Terms | Otuska            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Upfront payments received   $ 50,000        
Potential regulatory milestone revenue   $ 50,000        
Revenues     $ 13   $ 117  
License Agreement Terms | Otuska | Minimum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Tiered royalty percentages on future sales   10.00%        
License Agreement Terms | Otuska | Maximum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Tiered royalty percentages on future sales   20.00%        
License Agreement Terms | Riptide Bioscience, Inc.            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Upfront license fee $ 6,000          
Research and development $ 4,000